Validation of EORTC QLQ-C30 questionnaire in its Tunisian version

##plugins.themes.academic_pro.article.sidebar##

Published Mar 30, 2025
https://doi.org/10.62438/tunismed.v103i4.5260
Download
pdf
Vol. 103 No. 4 (2025): Tunis Med Apr 2025

##plugins.themes.academic_pro.article.main##

Soraya Fenniche
Pulmonology department Pavilion 4, Abderrahmen Mami hospital Ariana , Faculty of medicine of Tunis, University of Tunis El manar, Tunis, Tunisia
Nidhal Belloumi
Pulmonology department Pavilion 4, Abderrahmen Mami hospital Ariana , Faculty of medicine of Tunis, University of Tunis El manar, Tunis, Tunisia
https://orcid.org/0000-0002-8589-7026
Chaima Habouria
Pulmonology department Pavilion 4, Abderrahmen Mami hospital Ariana , Faculty of medicine of Tunis, University of Tunis El manar, Tunis, Tunisia
Imene Bachouch
Pulmonology department Pavilion 4, Abderrahmen Mami hospital Ariana , Faculty of medicine of Tunis, University of Tunis El manar, Tunis, Tunisia
Fatma Chermiti
Pulmonology department Pavilion 4, Abderrahmen Mami hospital Ariana , Faculty of medicine of Tunis, University of Tunis El manar, Tunis, Tunisia

Abstract

Objective: To test the validity and reliability of The European Organization for Research and Treatment of Cancer (EORTC) core (QLQ-C30) in its Tunisian dialectal version for lung cancer patients.


Methods: A total of 300 patients under a chemotherapy regimen for lung cancer were enrolled in this cross-sectional study. Participants had to answer EORTC QLQ-C30 auto-questionnaire in the Tunisian version, then in the Arabic version 15 days later. Statistical analyses were performed by SPSS 22.


Results: The Tunisian version was found reliable and valid for Tunisian cancer patients. Seven of the 8 multi-item scales of QLQ-C30 had high reliability (Cronbach’s α >0.7). In our analysis, the most determinative subscales of QLQ-C30 on global health were physical functioning, cognitive functioning, fatigue, and dyspnea. Correlation with the Arabic version was nearly a perfect mismatching; all sub-scale mean scores were statistically correlated. The inter-class correlations confirmed the external convergent validity. Discriminant validity was supported since the correlation value of a symptom scale score with other similar scales was higher than any functional scale, and inversely.


Conclusions: The Tunisian version of EORTC QLQ-C30, recently written is a reliable and valid tool to assess the quality of life of Tunisian lung cancer patients.

Keywords:

Non small cell lung carcinoma , Quality of life, Validation , EORTC QLQ-C30

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

  1. Park KU. Assessment of change of quality of life in terminally ill patients under cancer
  2. pain management using the EORTC Core Quality of Life Questionnaire (QLQ-C30) in a
  3. Korean sample. Oncology. 2008;74 Suppl 1:7–12.
  4. Ameri H, Yousefi M, Yaseri M, Nahvijou A, Arab M, Akbari Sari A. Mapping EORTC-QLQC30 and QLQ-CR29 onto EQ-5D-5L in Colorectal Cancer Patients. J Gastrointest Cancer.
  5. Apr 12;
  6. Demirci S, Eser E, Ozsaran Z, Tankisi D, Aras AB, Ozaydemir G, et al. Validation of the
  7. Turkish versions of EORTC QLQ-C30 and BR23 modules in breast cancer patients. Asian
  8. Pac J Cancer Prev APJCP. 2011;12(5):1283–7.
  9. El ayoubi H. Comparison of Reliability and Validity of the Breast Cancer depression
  10. anxiety stress scales (DASS-21) with the Beck Depression Inventory-(BDI-II) and
  11. Hospital Anxiety and Depression Scale (HADS). Int J Behav Res Psychol. 2016;4(4):197–
  12. Gadisa DA, Gebremariam ET, Ali GY. Reliability and validity of Amharic version of EORTC
  13. QLQ-C30 and QLQ-BR23 modules for assessing health-related quality of life among
  14. breast cancer patients in Ethiopia. Health Qual Life Outcomes. 2019 Dec;17(1):182.
  15. Musarezaie A, Khaledi F, Esfahani HN, Ghaleghasemi TM. Factors affecting quality of life and fatigue in patients with leukemia under chemotherapy. J Educ Health Promot.
  16. ;3:64.
  17. Pompili C, Koller M, Velikova G, Franks K, Absolom K, Callister M, et al. EORTC QLQ-C30
  18. summary score reliably detects changes in QoL three months after anatomic lung
  19. resection for Non-Small Cell Lung Cancer (NSCLC). Lung Cancer Amst Neth.
  20. ;123:149–54.
  21. Oñate-Ocaña LF, Alcántara-Pilar A, Vilar-Compte D, García-Hubard G, Rojas-Castillo E,
  22. Alvarado-Aguilar S, et al. Validation of the Mexican Spanish version of the EORTC C30
  23. and STO22 questionnaires for the evaluation of health-related quality of life in patients
  24. with gastric cancer. Ann Surg Oncol. 2009 Jan;16(1):88–95.
  25. Tan ML, Idris DB, Teo LW, Loh SY, Seow GC, Chia YY, et al. Validation of EORTC QLQC30 and QLQ-BR23 questionnaires in the measurement of quality of life of breast cancer
  26. patients in Singapore. Asia-Pac J Oncol Nurs. 2014 Apr;1(1):22–32.
  27. Tomaszewski KA, Püsküllüoğlu M, Biesiada K, Bochenek J, Nieckula J, Krzemieniecki K.
  28. Validation of the Polish Version of the EORTC QLQ-C30 and the QLQ-OG25 for the
  29. Assessment of Health-Related Quality of Life in Patients with Esophagi-Gastric Cancer. J
  30. Psychosoc Oncol. 2013 Mar;31(2):191–203.
  31. Eberhardt WEE, Mitchell A, Crowley J, Kondo H, Kim YT, Turrisi A, et al. The IASLC Lung
  32. Cancer Staging Project: Proposals for the Revision of the M Descriptors in the
  33. Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. J Thorac Oncol Off
  34. Publ Int Assoc Study Lung Cancer. 2015 Nov;10(11):1515–22.
  35. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE, et al. The
  36. IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings
  37. in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac
  38. Oncol Off Publ Int Assoc Study Lung Cancer. 2016 Jan;11(1):39–51.
  39. Huijer HAS, Sagherian K, Tamim H. Validation of the Arabic version of the EORTC quality
  40. of life questionnaire among cancer patients in Lebanon. Qual Life Res. 2013
  41. Aug;22(6):1473–81.
  42. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European
  43. Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument
  44. for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar
  45. ;85(5):365–76.
  46. Fayer P, Aaronson NK, Bjordal K, Sullian M. EORTC QLQ-C30 Scoring Manual. [Internet].
  47. EORTC Quality of Life Group, Bressels; 1995. Available from:
  48. https://www.eortc.org/app/uploads/sites/2/2018/02/SCmanual.pdf
  49. Nunnally JC, Bernstein IH. Psychometric theory. 3rd ed. New York: McGraw-Hill; 1994.
  50. p. (McGraw-Hill series in psychology).
  51. DeVellis RF. Scale development: theory and applications. Fourth edition. Los Angeles:
  52. SAGE; 2017. 262 p.
  53. Hays RD, Hayashi T. Beyond internal consistency reliability: Rationale and user‟s guide
  54. for Multitrait Analysis Program on the microcomputer. Behav Res Methods Instrum
  55. Comput. 1990 Mar 1;22(2):167–75.
  56. Fayers PM, Machin D. Quality of life: The assessment, analysis, and reporting of patient reported outcomes. Third edition. Chichester, West Sussex, UK ; Hoboken, NJ: John Wiley & Sons Inc; 2016.
  57. Everitt B. The Cambridge dictionary of statistics. 2nd ed. Cambridge, UK ; New York:
  58. Cambridge University Press; 2002. 410 p.
  59. Yun YH, Park YS, Lee ES, Bang SM, Heo DS, Park SY, et al. Validation of the Korean
  60. version of the EORTC QLQ-C30. Qual Life Res Int J Qual Life Asp Treat Care Rehabil.
  61. May;13(4):863–8.
  62. Shih CL, Chen CH, Sheu CF, Lang HC, Hsieh CL. Validating and Improving the Reliability
  63. of the EORTC QLQ-C30 Using a Multidimensional Rasch Model. Value Health. 2013
  64. Jul;16(5):848–54.
  65. Jaiyesimi AO, Sofela EA, Rufai AA. Health related quality of life and its determinants in
  66. Nigerian breast cancer patients. Afr J Med Med Sci. 2007 Sep;36(3):259–65.
  67. Kootstra J, Hoekstra-Weebers JEHM, Rietman H, de Vries J, Baas P, Geertzen JHB, et al.
  68. Quality of life after sentinel lymph node biopsy or axillary lymph node dissection in stage
  69. I/II breast cancer patients: a prospective longitudinal study. Ann Surg Oncol. 2008
  70. Sep;15(9):2533–41.
  71. Cocks K, Wells JR, Johnson C, Schmidt H, Koller M, Oerlemans S, et al. Content validity
  72. of the EORTC quality of life questionnaire QLQ-C30 for use in cancer. Eur J Cancer Oxf
  73. Engl 1990. 2023 Jan;178:128–38.
  74. Daroszewski C, Stasiewicz M, Jaźwińska-Tarnawska E, Rachwalik A, Mura E, LubochKowal J, et al. Quality of Life in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Palliative Chemotherapy. Adv Exp Med Biol. 2019;1160:11–8.
  75. Chie WC, Yang CH, Hsu C, Yang PC. Quality of life of lung cancer patients: validation of
  76. the Taiwan Chinese version of the EORTC QLQ-C30 and QLQ-LC13. Qual Life Res Int J
  77. Qual Life Asp Treat Care Rehabil. 2004 Feb;13(1):257–62.
  78. Dean GE, Abu Sabbah E, Yingrengreung S, Ziegler P, Chen H, Steinbrenner LM, et al.
  79. Sleeping with the enemy: sleep and quality of life in patients with lung cancer. Cancer
  80. Nurs. 2015 Feb;38(1):60–70.
  81. Brown ML, Lipscomb J, Snyder C. The burden of illness of cancer: economic cost and
  82. quality of life. Annu Rev Public Health. 2001;22:91–113.
  83. Kajimoto Y, Honda K, Suzuki S, Mori M, Tsubouchi H, Nakao K, et al. Association
  84. between financial toxicity and health-related quality of life of patients with gynecologic
  85. cancer. Int J Clin Oncol. 2023 Mar;28(3):454–67.
  86. Shim S, Kang D, Kim N, Han G, Lim J, Kim H, et al. Validation of Korean Version of the
  87. COmprehensive Score for financial Toxicity (COST) Among Breast Cancer Survivors.
  88. Cancer Res Treat. 2022 Jul;54(3):834–41.
  89. Dar MA, Chauhan R, Trivedi V, Kumar R, Dhingra S. Assessing the Prevalence of
  90. Financial Toxicity, its Predictors and Association with Health- Related Quality of Life
  91. Among Radiation Oncology Patients in India: A Cross-Sectional Patient Reported
  92. Outcome Study. Int J Radiat Oncol Biol Phys. 2023 May 1;116(1):157–65.
  93. Belloumi N, Maalej Bellaj S, Bachouche I, Chermiti Ben Abdallah F, Fenniche S.
  94. Comparison of Sleep Quality before and after Chemotherapy in Locally Advanced
  95. Nonsmall Cell Lung Cancer Patients: A Prospective Study. Sleep Disord. 2020 Jul
  96. ;2020:1–8.
  97. Asiimwe JB, Nagendrappa PB, Atukunda EC, Kamatenesi MM, Nambozi G, Tolo CU, et al.
  98. Prevalence of the Use of Herbal Medicines among Patients with Cancer: A Systematic
  99. Review and Meta-Analysis. Evid-Based Complement Altern Med ECAM.
  100. ;2021:9963038.
  101. Molassiotis A, Fernández-Ortega P, Pud D, Ozden G, Scott JA, Panteli V, et al. Use of
  102. complementary and alternative medicine in cancer patients: a European survey. Ann
  103. Oncol Off J Eur Soc Med Oncol. 2005 Apr;16(4):655–63.
  104. Wode K, Henriksson R, Sharp L, Stoltenberg A, Hök Nordberg J. Cancer patients‟ use of complementary and alternative medicine in Sweden: a cross-sectional study. BMC
  105. Complement Altern Med. 2019 Mar 13;19(1):62.